# Trametinib With GSK2141795 in BRAF Wild-type Melanoma

> **NCT01941927** · PHASE2 · COMPLETED · sponsor: **Adil Daud** · enrollment: 20 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** Trametinib (GSK1120212)
- **DRUG:** GSK2141795

## Key facts

- **NCT ID:** NCT01941927
- **Lead sponsor:** Adil Daud
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09-10
- **Primary completion:** 2014-10-14
- **Final completion:** 2017-05-03
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2020-02-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01941927

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01941927, "Trametinib With GSK2141795 in BRAF Wild-type Melanoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01941927. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*